22.08.2023
Arctic Bioscience will publish its financial results for the half year 2023 on Tuesday 29th of August, at 08:00 CET.
The same day at 12:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience.
Webcast details:
Date: Tuesday 29th of August 2023
Time: 12:00 CET
Format: Webcast and Q&A
Language: English
The presentation can be accessed through the Company’s website, or with the link below:
Link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230829_3
Participants will be required to register to view the webcast and participate in the Q&A.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.